PolyPid to outline long-term growth strategy at virtual investor day
PYPD•PolyPid will host a virtual Investor Day on October 28, 2026, to outline its “PolyPid 2030” growth and pipeline strategy. The company will update investors on D-PLEX₁₀₀, which is under FDA priority review with a November 28, 2026, decision target, and introduce diabetic foot infection candidate PD01B.
1. Investor day plans
PolyPid will hold its virtual Investor Day on October 28, 2026, at 11:30 a.m. ET. Management plans to outline its “PolyPid 2030” long-term growth and pipeline strategy.
2. Pipeline updates
The company will discuss D-PLEX₁₀₀ for colorectal surgical infection prevention, which is under FDA priority review with a November 28, 2026, decision target. Management will also introduce PD01B, a diabetic foot infection treatment candidate based on Kynatrix delivery technology. Warren S. Joseph will discuss diabetic foot infections, treatment limitations and the potential role of locally delivered, controlled-release antibiotics.
